Biotechnology - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

1 to 25 of 2293 results

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

27-08-2014

The UK’s drugs watch dog, the National Institute for Health and Care Excellence (NICE), has recommended…

Biogen IdecBiotechnologyCNS DiseasesMultiple sclerosisRegulationTecfideraUK

Early stage data in non-Hodgkins lymphoma  trial prompts surge in Kite Pharma's shares

Early stage data in non-Hodgkins lymphoma trial prompts surge in Kite Pharma's shares

27-08-2014

Oncology biopharma specialist Kite Pharma has seen its share price soar as much as 49.5% on the back…

anti-CD19-CARBiotechnologyCD19-CAR TChemotherapyChimeric antigen receptorKite PharmaLymphomaOncologyResearchUSA

Merck Serono starts building $105 million plant in Nantong, China

Merck Serono starts building $105 million plant in Nantong, China

27-08-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has started construction on its new pharmaceutical…

BiotechnologyChinaMerck KGaAMerck SeronoNantongPharmaceutical manufacturing facilityProduction

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

26-08-2014

Canadian regulator Health Canada has approved US Biotech major Biogen Idec’s Eloctate (antihemophilic…

Biogen IdecBiotechnologyCanadaEloctateHematologyRegulationSwedish Orphan Biovitrum

Advaxis and Merck & Co collaborate on prostate cancer

Advaxis and Merck & Co collaborate on prostate cancer

26-08-2014

US cancer immunotherapies firm Advaxis has entered into a clinical trial collaboration agreement with…

AdvaxisADXS-PSABiotechnologyLicensingMerck & CoOncologypembrolizumabResearch

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

26-08-2014

Ireland-headquartered biotech firm Alkermes has submitted a New Drug Application to the US Food and Drug…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyNeurologicalRegulationUSA

J&J affiliate Cilag GmbH International acquires Covagen

J&J affiliate Cilag GmbH International acquires Covagen

25-08-2014

Cilag GmbH International, an affiliate of US health care giant Johnson & Johnson’s Janssen companies,…

Anti-Arthritics/RheumaticsBiotechnologyCilag GmbH InternationalCovagenFynomAbInflammatory diseasesJanssenJohnson & JohnsonMergers & Acquisitions

Regado Biosciences permanently halts REGULATE-PCI trial

Regado Biosciences permanently halts REGULATE-PCI trial

25-08-2014

US-based cardiovascular specialist Regado Biosciences Regado Biosciences has announced the permanent…

BiotechnologyCardio-vascularRegadoResearchRevolixys

ViaCyte gets $20 million in deal with Janssen

ViaCyte gets $20 million in deal with Janssen

22-08-2014

Privately held US regenerative medicine company ViaCyte has entered into a rights agreement with Janssen…

BiotechnologyDiabetesEndocrine systemFinancialJanssenJohnson & JohnsonLicensingUSAVC-01ViaCyte

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

21-08-2014

Surveyed managed care organizations (MCOs) anticipate that their costs of covering biologic treatments…

Anti-Arthritics/RheumaticsBiotechnologyFinancialHealthcareImmunologicals

Positive Ph III data for Amicus’ migalastat as Fabry monotherapy

Positive Ph III data for Amicus’ migalastat as Fabry monotherapy

21-08-2014

US biopharma company Amicus Therapeutics has revealed positive 18-month data from its second Phase III…

Amicus TherapeuticsBiotechnologymigalastatRare diseasesRegulationResearch

AstraZeneca to collaborate with Illumina on gene sequencing panel for diagnostic tests

AstraZeneca to collaborate with Illumina on gene sequencing panel for diagnostic tests

21-08-2014

Anglo-Swedish drug major AstraZeneca is to collaborate with gene sequencing company Illumina to develop…

AstraZenecaBiotechnologyGeneticsIlluminaOncologyPersonalized healthcareResearch

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

20-08-2014

US biopharmaceutical firm Emergent BioSolutions and Germany’s MorphoSys have entered into an agreement…

BiotechnologyEmergent BioSolutionsES414GermanyLicensingMOR209/ES414MorphoSysOncologyProstate cancerUSA

Roche to partner with the Garvan Institute in genomics research

Roche to partner with the Garvan Institute in genomics research

20-08-2014

Swiss drug major Roche and the Garvan Institute of Medical Research are to collaborate in the development…

AustraliaBiotechnologyDNA sequencingGarvan InstituteGeneticsGenomics technologiesJohn MattickResearchRocheSwitzerland

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

20-08-2014

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued final draft…

BiotechnologyCelgene Corp.Myelodysplastic syndromesOncologyPricingRegulationRevlimidUK

Genzyme’s Cerdelga gets FDA approval for Gaucher disease

Genzyme’s Cerdelga gets FDA approval for Gaucher disease

20-08-2014

The US Food and Drug Administration late yesterday approved Cerdelga (eliglustat) for the long-term treatment…

ActelionBiotechnologyCerdelgaCerezymeGenzymeRare diseasesRegulationSanofiUSAZavesca

Further positive Ph III results for Amgen’s AMG 416 in secondary hyperparathyroidism

Further positive Ph III results for Amgen’s AMG 416 in secondary hyperparathyroidism

19-08-2014

USA-based Amgen has released positive data from a second placebo-controlled Phase III study evaluating…

AMG 416AmgenBiotechnologyClinical researchHemodialysisNephrology and HepatologyResearchUSA

Novartis makes investment in stem cell company Gamida Cell with option agreement

Novartis makes investment in stem cell company Gamida Cell with option agreement

19-08-2014

Swiss drug major Novartis has signed an investment and option agreement with Israeli stem cell specialist…

BiotechnologyFinancialGamida CellHematologyIsraelNovartisStem cell specialistSwitzerland

Pharming acquires Transgenic Rabbit Models assets and accesses five new product leads

Pharming acquires Transgenic Rabbit Models assets and accesses five new product leads

19-08-2014

Dutch biotech company Pharming Group says that, through the acquisition of certain assets of Transgenic…

BiotechnologyMergers & AcquisitionsNetherlandsPharmingPharming Group NVTreatment of Pompe’s disease

HUYA to partner with Changzhou Center for Biotech Development to promote local innovation

HUYA to partner with Changzhou Center for Biotech Development to promote local innovation

18-08-2014

Chinese company HUYA Bioscience has announced a partnership with Changzhou Center for Biotech Development,…

BiotechnologyChangzhouChinaHUYA BioscienceResearch

Biogen Idec’s Plegridy gains US approval for multiple sclerosis

Biogen Idec’s Plegridy gains US approval for multiple sclerosis

17-08-2014

The US Food and Drug Administration has approved US biotech firm Biogen Idec’s (Nasdaq: BIIB) Plegridy…

Biogen IdecBiotechnologyNeurologicalPlegridyRegulationUSA

1 to 25 of 2293 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top